Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Thermo Fisher Scientific Inc.. (9/28/15). "Press Release: International Working Group on Antibody Validation Meets to Drive Toward More Effective Biomedical Research". Vancouver, BC.

Region Region Vancouver, BC
  Country Canada
Organisations Organisation Thermo Fisher Scientific Inc. (NYSE: TMO)
  Group Thermo Fisher (Group)
  Organisation 2 International Working Group on Antibody Validation (IWGAV)
Products Product analytical chemistry
  Product 2 HUPO 2015 Vancouver (14th Annual World Congress)
Persons Person Uhlén, Mathias (Royal Institute of Technology (SE) 201509 Professor of Microbiology)
  Person 2 Lindpaintner, Klaus (Thermo Fisher 201211– CSO before Strategic Diagnostics + Roche)

First Initiative of its Size and Scope to Establish Standards for Antibody Validation for both Antibody Producers and Users

The International Working Group on Antibody Validation, a group of leading authorities in the field of protein-binding technology, will hold its first meeting this week in Vancouver, Canada, coinciding with the Human Proteome Organization’s annual congress. The independent group, with operating expenses supported in part by Thermo Fisher Scientific, will develop guidelines for the validation of antibody specificity, functionality and reproducibility. Noted protein biochemist Mathias Uhlén, Ph.D., will chair the group.

“There is a critical need that has recently been highlighted in several high-profile publications for broadly accepted antibody quality and validation standards upon which the scientific community can rely,” said Dr. Uhlén, professor of microbiology, Royal Institute of Technology, Stockholm, Sweden. “I look forward to working with my esteemed fellow working group members to address this gap in a creative, timely and practical way and ensure the reliability of these essential tools of biomedical research.”

The goal of the working group is to develop common validation standards for antibodies. The working group will engage the broader scientific community in dialogue on the topic and interact with parallel initiatives in the field. Its goal is to publish consensus guidelines for both antibody users and providers. Delivery of the guidelines is targeted for fall 2016.

“Thermo Fisher Scientific is pleased to support the International Working Group on Antibody Validation. Antibody validation standards should provide users with confidence that an antibody can specifically recognize the intended target in appropriate assays,” said Klaus Lindpaintner, M.D., M.P.H., chief scientific officer, analytical technologies, Thermo Fisher Scientific. “Implementing optimized antibody validation standards should result in greater confidence among antibody users and more reliable and reproducible research outcomes.”

In addition to Dr. Uhlén, members of the International Working Group on Antibody Validation include:

> A. Bandrowski, Ph.D., Project Lead, Neuroscience Information Framework Project, University of California San Diego, San Diego, California

> Andrew Bradbury, Ph.D., Group Leader and Scientist, Biosciences Division, Los Alamos National Laboratory, Los Alamos, New Mexico

> Steven A. Carr, Ph.D., Director of Proteomics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts

> Emma Lundberg, Ph.D., Associate Professor, Department of Proteomics and Nanobiotechnology, Royal Institute of Technology, Stockholm, Sweden

> David L. Rimm, M.D., Ph.D., Professor of Pathology and of Medicine (Medical Oncology); Director of Pathology Tissue Services; Director of Translational Pathology, Yale University School of Medicine; New Haven, Connecticut

> Henry Rodriguez, Ph.D., M.B.A., Director, Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Washington, D.C.

> Michael Snyder, Ph.D., Professor and Chair of Genetics; Director, Center for Genomics and Personalized Medicine; Stanford University, Stanford, California

> Tadashi Yamamoto, M.D., Ph.D., Research leader, Research Professor, Biofluid Biomarker Center (BB-C): Center of Innovation satellite (COI-s) Institute for Research Collaboration and Promotion, Niigata University; Niigata, Japan

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion, and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit


Thermo Fisher Scientific Inc.
Ron O’Brien, 781-622-1242

Record changed: 2016-01-10


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Thermo Fisher (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [LSUS] – The Business Web Portal 600x60px

» top